PTC Therapeutics' researchers identify biochemical pathway important for modulating cell growth

SOUTH PLAINFIELD, NJ April 30, 2004 PTC Therapeutics, Inc. (PTC), today announced the first identification in humans of an enzyme complex underlying the metabolism of tRNA and mRNA, two integral components of cell proliferation. This research, published in the April 30th issue of the scientific journal Cell, provides compelling evidence for the existence of a new biochemical pathway that may lead to the discovery of new drugs for the treatment of proliferative disorders. Such disorders are characterized by rapidly and uncontrollably dividing cells and include malignancies such as leukemia, lymphoma, multiple myeloma, solid tumors, and inflammatory diseases such as psoriasis.

"The recent work by PTC's researchers is extraordinary in that it creates a physical, and possibly regulatory link between the pathways that create RNA messengers and those that create the translational machinery for turning those messages into proteins," said Dr. David R. Engelke, Director of the Program of Biomedical Sciences at the University of Michigan. "Researchers have always treated these processes as entirely separate sets of reactions. It is now clear that they are intertwined, whether investigating fundamental mechanisms in normal cells or searching for drug targets to identify novel therapeutics."

Dr. Christopher R. Trotta, Senior Scientist at PTC and Principal Investigator in this work comments: "Overexpression of tRNA and mRNA is a key factor in the deregulation of translation that allows cancer cells to grow uncontrollably. This newly discovered biochemical pathway represents an Achilles' Heel of tumor cell growth and opens a new door in the development of therapeutics."

(more) Expression of genetic information is an ordered, multi-step process that proceeds from DNA to RNA to protein. Deregulation of any step in this process can lead to a number of diseases. Messenger RNA and transfer RNA are required for the production of protein

Contact: Kerri Donnelly
908-222-7000 x 112
Euro RSCG Life NRP

Page: 1 2

Related biology news :

1. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
2. Belgian researchers explore revolutionary approach to angiogenesis
3. Award winning researchers reveal potential new role for Glivec
4. $7.5 Million grant to Yale researchers for role of viruses in cancer
5. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
6. Joslin researchers clarify mechanisms for beta-cell formation
7. Virginia Tech researchers to release findings on Smith River Project
8. Molecular motor myosin VI moves hand over hand, researchers say
9. ASU researchers demonstrate new technique that improves the power of atomic force micrscopy
10. Emory researchers map structure of anti-cancer molecule
11. Leukemia stem cells identified by Stanford researchers

Post Your Comments:

(Date:8/21/2020)... ... 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology ... and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application ... COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 study ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, ... Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, ...
(Date:8/7/2020)... SAN FRANCISCO (PRWEB) , ... August 06, 2020 ... ... the life sciences industry, is pleased to announce that Eric Chen and Jessica ... Vice President of Product Management & Strategy, respectively. , Eric Chen heads development ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... the life sciences and food industries, is pleased to announce that Charles Galea ... – Business Development. , Charles is an accomplished and results-driven sales executive with ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
(Date:7/10/2020)... (PRWEB) , ... July 09, 2020 , ... ... to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., F.A.C.P., ... and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. Nissenson ...
Breaking Biology Technology:
Cached News: